Opinion|Videos|March 20, 2024
Optimizing Hemophilia Treatment: Strategies and Adherence
Steven W. Pipe, MD, shares insights on optimizing hemophilia treatment schedules and minimizing hoarding of factor VIII prophylaxis or emicizumab for improved patient adherence.
Episodes in this series
This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.
Pipe addresses the critical issue of optimizing hemophilia treatment schedules and minimizing medication hoarding. The focus is on ensuring timely and infrequent reorders of prophylactic medications for patients. With a particular emphasis on emicizumab, given its extended dosing intervals, pharmacies often dispense 1 to 2 months' worth, effectively regulating the vial quantities at home. Unlike the factor replacement therapy era, where frequent dispensing was needed, emicizumab's lower intensity prophylaxis reduces the necessity for regular insurance doses. Pipe emphasizes the importance of communication among patients, health care providers, and pharmacies to match inventory with utilization, avoiding wastage and expiration. The discussion also delves into challenges with emicizumab vial sizes, highlighting the need for more options to accommodate individual patient weights. While adherence remains a consideration, the consequences of nonadherence with emicizumab are comparatively minimized, providing reassurance to patients. The interview underscores evolving strategies to optimize treatment efficiency, enhance patient adherence, and navigate the unique considerations associated with both factor replacement and emicizumab therapies in hemophilia care.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5